Nivien Therapeutics
San Francisco
About Nivien Therapeutics
Nivien Therapeutics developed the first small molecule inhibitors of the Hippo signaling pathway. Read the Nivien story in The Washington Post: https://www.washingtonpost.com/national/health-science/heres-what-happened-when-i-tried-to-develop-a-new-drug-for-a-deadly-cancer/2019/01/11/
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $600.0K
- Funding stage: Seed
- Last round: Seed (Dec 2017)
- Website: nivientherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/nivien-therapeutics-180064 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.